Unique ID issued by UMIN | UMIN000032164 |
---|---|
Receipt number | R000036689 |
Scientific Title | A study of biomarker predicting the effect of Nivolumab for unresectable advanced or recurrent gastric cancer. |
Date of disclosure of the study information | 2018/04/09 |
Last modified on | 2024/04/15 18:21:17 |
A study of biomarker predicting the effect of Nivolumab for unresectable advanced or recurrent gastric cancer.
Biomarker research of Nivolumab for gastic cancer.
A study of biomarker predicting the effect of Nivolumab for unresectable advanced or recurrent gastric cancer.
Biomarker research of Nivolumab for gastic cancer.
Japan |
Unresectable advanced or recurrent gastric cancer
Gastrointestinal surgery |
Malignancy
NO
To search predictive biomarker of Nivolumab treatment for unresectable advanced or recurrent gastric cancer by immunohistochemical examination.
Efficacy
Association between overall survival (OS) and the protein expression of each factor.
Observational
20 | years-old | <= |
Not applicable |
Male and Female
1) Age over 20 years old.
2) Histologically diagnosed unresectable advanced or recurrent gastric or esophagogastric junction adenocarcinoma.
3) Tumor tissues for biomarker examination are available.
4) Treatment with more than 2 regimens is provided for unresectable advanced or recurrent gastric or esophagogastric cancer.
5) Nivolumab treatment is planning to go, is going, or was performed as a treatment with later than third rejimens.
6) Written informed consent.
1) Synchronous or metachronous (within 5 years) double cancers, except for intraepithelial tumor (Carcinoma in situ) or intramucosal tumor curatively resectable by local therapy at the time of Nivolumab treatment.
2) History of medical therapy for the purpose of the immune checkpoint inhibitors such as antiPD-1 antibody, antiPD-L1 antibody, antiCTLA-4 antibody or other T cell regulator before the Nivolumab treatment.
3) Having severe psychological illness and difficult to make a judgement for participation in the study.
4) Judged to be unfit to participate in the study by investigater.
200
1st name | Yuichiro |
Middle name | |
Last name | Doki |
Graduated School of Medicine, Osaka University
Department of Gastroenterological Surgery
565-0871
2-2-E2, Yamadaoka, Suita City, Osaka
06-6879-3251
ydoki@gesurg.med.osaka-u.ac.jp
1st name | Yukinori |
Middle name | |
Last name | Kurokawa |
Graduated School of Medicine, Osaka University
Department of Gastroenterological Surgery
565-0871
2-2-E2, Yamadaoka, Suita City, Osaka
06-6879-3251
ykurokawa@gesurg.med.osaka-u.ac.jp
Osaka University
none
Other
Osaka University
2-2-E2, Yamadaoka, Suita City, Osaka
06-6879-3251
thagi@gesurg.med.osaka-u.ac.jp
NO
2018 | Year | 04 | Month | 09 | Day |
Unpublished
Open public recruiting
2017 | Year | 10 | Month | 01 | Day |
2018 | Year | 02 | Month | 14 | Day |
2018 | Year | 02 | Month | 14 | Day |
2022 | Year | 03 | Month | 31 | Day |
Observational study
2018 | Year | 04 | Month | 09 | Day |
2024 | Year | 04 | Month | 15 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036689
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |